$ARMP
Armata Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023004014 Filed on March 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $796.0K $1.051M $5.508M
YoY Change -35.6% 6.27% 23.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.538M $1.810M $7.437M
YoY Change 27.99% -18.58% -10.19%
% of Gross Profit
Research & Development $9.604M $9.569M $35.02M
YoY Change 19.63% 98.77% 74.95%
% of Gross Profit
Depreciation & Amortization $200.0K $245.0K $900.0K
YoY Change 0.0% -11.55% -25.0%
% of Gross Profit
Operating Expenses $12.14M $11.38M $42.45M
YoY Change 21.29% 61.7% 50.04%
Operating Profit -$11.35M -$36.95M
YoY Change 29.3% 55.09%
Interest Expense -$3.144M $14.00K $0.00
YoY Change -314500.0% 1300.0% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.144M $29.00K
YoY Change -314500.0% -95.65%
Pretax Income -$14.49M -$10.31M -$36.92M
YoY Change 65.15% 70.56% 59.43%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.49M -$10.31M -$36.92M
YoY Change 65.15% 70.56% 59.43%
Net Earnings / Revenue -1820.35% -981.35% -670.24%
Basic Earnings Per Share -$0.40 -$1.08
Diluted Earnings Per Share -$0.40 -$0.29 -$1.08
COMMON SHARES
Basic Shares Outstanding 36.14M 36.14M 34.29M
Diluted Shares Outstanding 36.05M 34.29M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.11M $14.85M $14.85M
YoY Change -45.9% 44.36% 44.36%
Cash & Equivalents $25.10M $14.85M $14.85M
Short-Term Investments
Other Short-Term Assets $13.49M $12.20M $12.20M
YoY Change 488.78% 159.08% 159.08%
Inventory
Prepaid Expenses $3.664M
Receivables
Other Receivables $8.531M
Total Short-Term Assets $38.60M $27.05M $27.05M
YoY Change -20.75% 80.37% 80.37%
LONG-TERM ASSETS
Property, Plant & Equipment $5.437M $3.617M $46.65M
YoY Change 141.75% 62.93% 22.54%
Goodwill $3.490M $3.490M
YoY Change 0.0% 0.0%
Intangibles $10.26M $10.26M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $2.453M $2.429M $8.389M
YoY Change 44.72% 38.4% 183.89%
Total Long-Term Assets $70.18M $68.79M $68.79M
YoY Change 18.82% 25.59% 25.59%
TOTAL ASSETS
Total Short-Term Assets $38.60M $27.05M $27.05M
Total Long-Term Assets $70.18M $68.79M $68.79M
Total Assets $108.8M $95.83M $95.83M
YoY Change 0.94% 37.36% 37.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.000M $1.678M $4.328M
YoY Change 45.48% 47.45% 280.32%
Accrued Expenses $14.03M $20.55M $20.55M
YoY Change 402.94% 552.84% 552.84%
Deferred Revenue
YoY Change
Short-Term Debt $32.39M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.42M $24.87M $24.87M
YoY Change 725.81% 416.68% 416.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.84M $31.80M $31.80M
YoY Change -13.77% -12.82% -12.82%
Total Long-Term Liabilities $31.84M $31.80M $31.80M
YoY Change -13.77% -12.82% -12.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.42M $24.87M $24.87M
Total Long-Term Liabilities $31.84M $31.80M $31.80M
Total Liabilities $86.33M $59.75M $59.75M
YoY Change 86.76% 34.67% 34.67%
SHAREHOLDERS EQUITY
Retained Earnings -$254.3M -$239.8M
YoY Change 20.14% 18.2%
Common Stock $361.0K $361.0K
YoY Change 0.0% 33.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.45M $36.08M $36.08M
YoY Change
Total Liabilities & Shareholders Equity $108.8M $95.83M $95.83M
YoY Change 0.94% 37.36% 37.36%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$14.49M -$10.31M -$36.92M
YoY Change 65.15% 70.56% 59.43%
Depreciation, Depletion And Amortization $200.0K $245.0K $900.0K
YoY Change 0.0% -11.55% -25.0%
Cash From Operating Activities -$17.57M -$10.49M -$32.48M
YoY Change 399.86% 21.95% 37.78%
INVESTING ACTIVITIES
Capital Expenditures $2.010M -$455.0K $2.211M
YoY Change 751.69% 99.56% 69.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.010M $455.0K -$2.211M
YoY Change 751.69% -299.56% 69.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $44.39M
YoY Change 68.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.59M -500.0K 44.02M
YoY Change -33.69% -107.1% 72.49%
NET CHANGE
Cash From Operating Activities -17.57M -10.49M -32.48M
Cash From Investing Activities -2.010M 455.0K -2.211M
Cash From Financing Activities 29.59M -500.0K 44.02M
Net Change In Cash 10.01M -10.53M 9.324M
YoY Change -75.5% 488.93% 1359.15%
FREE CASH FLOW
Cash From Operating Activities -$17.57M -$10.49M -$32.48M
Capital Expenditures $2.010M -$455.0K $2.211M
Free Cash Flow -$19.58M -$10.03M -$34.69M
YoY Change 421.99% 19.83% 39.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36144706
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34294124
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24104146
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27112299
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37544
CY2022 dei Entity Registrant Name
EntityRegistrantName
ARMATA PHARMACEUTICALS, INC.
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5293000
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1549568
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4503 Glencoe Avenue
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Marina del Rey
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90292
CY2022 dei City Area Code
CityAreaCode
858
CY2022 dei Local Phone Number
LocalPhoneNumber
829-0829
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
ARMP
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
41900000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36144706
CY2022 dei Auditor Name
AuditorName
Ernst & Young, LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, CA
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14852000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10288000
CY2022Q4 armp Award Receivable
AwardReceivable
1936000
CY2021Q4 armp Award Receivable
AwardReceivable
2989000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10259000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1718000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27047000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
14995000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5960000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3617000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2220000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43035000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35852000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2022Q4 us-gaap Goodwill
Goodwill
3490000
CY2021Q4 us-gaap Goodwill
Goodwill
3490000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2429000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1755000
CY2022Q4 us-gaap Assets
Assets
95834000
CY2021Q4 us-gaap Assets
Assets
69768000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6034000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270000
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1828000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1035000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17011000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1509000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24873000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4814000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31804000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36480000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2022Q4 us-gaap Liabilities
Liabilities
59754000
CY2021Q4 us-gaap Liabilities
Liabilities
44371000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36144706
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27112299
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
271000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275493000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
227983000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239774000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202857000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25397000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95834000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69768000
CY2022 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
5508000
CY2021 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
4474000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35017000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20015000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7437000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8281000
CY2022 us-gaap Operating Expenses
OperatingExpenses
42454000
CY2021 us-gaap Operating Expenses
OperatingExpenses
28296000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-36946000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-23822000
CY2021 armp Gain Loss On Extinguishment Of Paycheck Protection Program Since Inception
GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception
726000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2021 us-gaap Interest Expense
InterestExpense
64000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
667000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36917000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-23155000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34294124
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24104146
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18857000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26306000
CY2021 armp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
291000
CY2021 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
106000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
322000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2882000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-23155000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25397000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44391000
CY2022 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
21000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3105000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36917000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
CY2022 us-gaap Profit Loss
ProfitLoss
-36917000
CY2021 us-gaap Profit Loss
ProfitLoss
-23155000
CY2022 us-gaap Depreciation
Depreciation
892000
CY2021 us-gaap Depreciation
Depreciation
1169000
CY2021 armp Gain Loss On Extinguishment Of Paycheck Protection Program Loan
GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan
722000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3105000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2882000
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
60000
CY2021 armp Accrued Interest For Deferred Consideration On Asset Acquisition
AccruedInterestForDeferredConsiderationOnAssetAcquisition
586000
CY2022 armp Increase Decrease In Award Receivable
IncreaseDecreaseInAwardReceivable
-1053000
CY2021 armp Increase Decrease In Award Receivable
IncreaseDecreaseInAwardReceivable
2428000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3665000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
184000
CY2022 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
793000
CY2021 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
472000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
3643000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
499000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8715000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1950000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32481000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23575000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2211000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1304000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2211000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1304000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1414000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
500000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
44391000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26319000
CY2022 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
125000
CY2021 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
613000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44016000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25518000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9324000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
639000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10849000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8669000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26056000
CY2021 armp Forgiveness Related To Paycheck Protection Program
ForgivenessRelatedToPaycheckProtectionProgram
722000
CY2021 armp Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
13000
CY2022 us-gaap Contribution Of Property
ContributionOfProperty
78000
CY2021 us-gaap Contribution Of Property
ContributionOfProperty
38000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14852000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10288000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5960000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2022 us-gaap Substantial Doubt About Going Concern Managements Evaluation
SubstantialDoubtAboutGoingConcernManagementsEvaluation
The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24031807
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19210919
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14720000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12445000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11103000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10225000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3617000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2220000
CY2022 us-gaap Depreciation
Depreciation
900000
CY2021 us-gaap Depreciation
Depreciation
1200000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1678000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1138000
CY2022Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
2650000
CY2021Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
529000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1706000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
603000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6034000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-32228000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21714000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4689000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1441000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36917000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23155000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.073
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.286
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.272
CY2022 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
0.005
CY2021 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
0.008
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42525000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36405000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19103000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16306000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3192000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2467000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
929000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1301000
CY2022Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
13660000
CY2021Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
10631000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1452000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1174000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80861000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68284000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68818000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58251000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12043000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10033000
CY2022Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
12043000
CY2021Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
10033000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
15120000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13110000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077000
CY2020Q2 armp Operating Lease Base Rent
OperatingLeaseBaseRent
1900000
CY2020Q2 armp Annual Increase In Rent Percentage
AnnualIncreaseInRentPercentage
0.03
CY2020Q2 armp Operating Lease Base Rent End Of Lease Term
OperatingLeaseBaseRentEndOfLeaseTerm
2500000
CY2020Q2 armp Lease And Rental Abatement Credit Period
LeaseAndRentalAbatementCreditPeriod
P6M
CY2020Q2 armp Lease And Rental Abatement Credit
LeaseAndRentalAbatementCredit
800000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11700000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11000000.0
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1289
CY2021Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P16Y
CY2021Q4 armp Base Annual Rent To Be Paid Year Three
BaseAnnualRentToBePaidYearThree
250000
CY2021Q4 armp Maximum Allowance For Tenant Improvements Receivable
MaximumAllowanceForTenantImprovementsReceivable
7300000
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.118
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
37000000.0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33800000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5000000.0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2904000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4512000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5139000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5452000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
49395000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
72695000
CY2022Q4 armp Short Term Variable Lease Payment Amount
ShortTermVariableLeasePaymentAmount
14954000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38834000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
48815000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17011000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31804000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
6300000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2700000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2022 us-gaap Interest Expense
InterestExpense
0
CY2021 us-gaap Interest Expense
InterestExpense
100000
CY2019Q2 armp Revenue Expected Milestone Receivable Amount
RevenueExpectedMilestoneReceivableAmount
1500000
CY2019Q2 armp Agreement Option Fee Amount
AgreementOptionFeeAmount
1500000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2022Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
45000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20549338
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3105000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2882000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2409682
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1254500
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.95
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38287
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.29
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
44000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
273092
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.94
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3352803
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.32
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3352803
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.32
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1438123
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.17
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M1D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3352803
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20549338
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24512459
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
armp-20221231_lab.xml Edgar Link unprocessable
armp-20221231_cal.xml Edgar Link unprocessable
0001558370-23-004014-index-headers.html Edgar Link pending
0001558370-23-004014-index.html Edgar Link pending
0001558370-23-004014.txt Edgar Link pending
0001558370-23-004014-xbrl.zip Edgar Link pending
armp-20221231.xsd Edgar Link pending
armp-20221231x10k.htm Edgar Link pending
armp-20221231x10k003.jpg Edgar Link pending
armp-20221231x10k004.jpg Edgar Link pending
armp-20221231x10k005.jpg Edgar Link pending
armp-20221231x10k006.jpg Edgar Link pending
armp-20221231x10k007.jpg Edgar Link pending
armp-20221231x10k008.jpg Edgar Link pending
armp-20221231x10k009.jpg Edgar Link pending
armp-20221231x10k010.jpg Edgar Link pending
armp-20221231x10k011.jpg Edgar Link pending
armp-20221231xex21d1.htm Edgar Link pending
armp-20221231xex23d1.htm Edgar Link pending
armp-20221231xex31d1.htm Edgar Link pending
armp-20221231xex31d2.htm Edgar Link pending
armp-20221231xex32d1.htm Edgar Link pending
armp-20221231xex32d2.htm Edgar Link pending
armp-20221231xex4d9.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
armp-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
armp-20221231_pre.xml Edgar Link unprocessable
armp-20221231x10k_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending